MSI conducted a Phase 2 Study, the “Horizon Study”, which was designed to evaluate the efficacy and safety of MSI-195 (Strada™) in patients suffering from MDD who had had an inadequate response to current antidepressant therapy.
The HORIZON trial was a US, double-blind, randomized, placebo-controlled, Phase 2, add-on clinical trial investigating the ability of Strada™ plus current anti-depressant therapy to decrease depressive symptoms based on the Hamilton Depression Rating Scale (HAM-D17), with over 300 patients enrolled with Major Depressive Disorder(MDD) who had had an inadequate response to current anti-depressant therapy. This trial focused on MDD patients who failed to respond to anti-depressant therapy for at least 6 weeks. The trial was designed to measure safety and efficacy over an 8 week period.
For more information on the HORIZON Study, please visit www.clinicaltrials.gov.